🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Dr. Maen Abdelrahim Maen Abdelrahim, MD, PhD, Pharm.B Houston Methodist unveils his insights on targeting Claudin 18.2 in pancreatic cancer, talks about anti CLDN 18.2 targeting antibody, bispecific T cell engagers, and CAR-T. #DAVAGI

There's still time to register and learn from these amazing experts! Dr. Nancy Kemeny MSKCC, Lewis Roberts Milind Javle Eugene J. Koay, MD, PhD Colin Court Caitlin McIntyre @AlexParikhMD Blue Faery Jean-Nicolas Vauthey MD Maen Abdelrahim, MD, PhD, Pharm.B to name and few! See you soon! UT Health San Antonio Research University Health

Maen Abdelrahim, MD, PhD, Pharm.B discusses Immune checkpoint inhibitors pre and post transplant #SALCS24

Enjoying an Elite live cancer symposium chaired by my friend Sukeshi Arora MD UT Health San Antonio Research comprehensive discussions along the spectrum of liver malignancy ✨✨Milind Javle Maen Abdelrahim, MD, PhD, Pharm.B Adam Yopp

Following James Van Der Beek' colorectal cancer diagnosis announcement, our gastrointestinal oncologist Dr. Maen Abdelrahim, MD, PhD, Pharm.B explains what could be causing more cases of colorectal cancer among younger adults with KPRC 2 Houston. spr.ly/6015SoNrz

According to our study, led by Dr. Maen Abdelrahim, MD, PhD, Pharm.B, clofazimine shows promise for both reducing the toxicity and enhancing the efficacy of dual immune checkpoint blockade therapy, a discovery that could extend the revolutionary treatment to more patients. spr.ly/6019SAqlZ

Excited about our Inaugural GI Oncology Conference tomorrow. Join us to learn from esteemed speakers discussing hot topics in GI oncology!

This cozy coffee spot is all decked out for the holidays! 🎄✨ A perfect escape from the chilly Houston weather with a warm drink and festive vibes.!

«الكلوفازيمين» بديل فعال لتقليل الآثار الجانبية وتعزيز الجهاز المناعي في محاربة السرطان aawsat.news/45dxq

Honored to announce the release of the first #TransplantOncology reference book, a significant milestone in this field. I want to express my gratitude to all the colleagues and contributors whose expertise and dedication made this achievement possible. Houston Methodist MD ILTS

«الكلوفازيمين» بديل فعال لتقليل الآثار الجانبية وتعزيز الجهاز المناعي في محاربة السرطان aawsat.news/45dxq

Time ⏰ to register 📝 for AHPBA 2025 🏖️

A plan started a year ago, come join AASLD and international speakers talking about MetALD, MASLD and ALD. See you in. Vegas in March. #livertwitter W Ray Kim Elliot Tapper Naim Alkhouri Alina Allen Altimmune, Inc. Juan Pablo (JP) Arab, MD  Novo Nordisk US Medical Boehringer Ingelheim akerotx

This joint initiative, led by Dr. Khurram Nasir, Dr. WilliamZoghbi and Rice’s Dr. Ashutosh Sabharwal, unites our academic medicine and research infrastructure with Rice University’s leadership in engineering, digital health and AI. Read on Houston Business Journal: spr.ly/6010vdhss

✨Newly published!✨ Detection of urine circulating tumor DNA using droplet digital PCR for predicting hepatocellular carcinoma recurrence 👉Free to download and read: oaepublish.com/articles/2394-… #HepatocellularCarcinoma #ctDNA #LiverCancer #livertwitter #HCCTWITTER #MedEd

❇️ At ASCO #GI25, we spoke with Dr. Maen Abdelrahim, MD, PhD, Pharm.B on the impact of UGT1A1*28 in patients with #mPDAC who were treated with #NALIRIFOX during NAPOLI 3. 📺 Does UGT1A1*28 status affect safety or dosing in patients? Watch the full interview to find out: buff.ly/4ggaju2

أول كتاب في العالم عن استخدام زراعة الأعضاء لعلاج مرض السرطان aawsat.news/4xmcv

2025 Annual Conference recordings are now available. #ccfac25

🔊 In a new interview with Dr. Maen Abdelrahim, MD, PhD, Pharm.B of Houston Methodist/Houston Methodist MD, he discusses his pioneering work in transplant oncology, a rapidly evolving subspecialty that works to expand treatment options for patients with liver cancer: buff.ly/2RiT3Ot